STOCK TITAN

Ocular Therapeutix (OCUL) Stock News, Mar-May 2024

OCUL NASDAQ

Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.

Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Ocular Therapeutix, Inc. (NASDAQ:OCUL) will be presenting at the OIS Retina and ARVO meetings in Seattle, Washington, from May 4-9, 2024. The Company will showcase its innovative therapies for wet age-related macular degeneration and diabetic retinopathy, with multiple presentations scheduled at the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
conferences
-
Rhea-AI Summary

Ocular Therapeutix™ announced plans to report first quarter 2024 financial results on May 7, 2024, and host an Investor Day in New York City on June 13, 2024. The event will focus on the company's corporate strategy and retinal disease pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.69%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags

FAQ

What is the current stock price of Ocular Therapeutix (OCUL)?

Ocular Therapeutix (OCUL) last closed at $5.86.

What is the market cap of Ocular Therapeutix (OCUL)?

The market cap of Ocular Therapeutix (OCUL) is approximately $1.3B.